|1.||Ferrara, Napoleone: 77 articles (06/2015 - 01/2002)|
|2.||Carmeliet, Peter: 69 articles (11/2015 - 02/2002)|
|3.||Rini, Brian I: 56 articles (11/2015 - 04/2004)|
|4.||Wang, Wei: 54 articles (11/2015 - 03/2002)|
|5.||Jain, Rakesh K: 53 articles (11/2015 - 03/2002)|
|6.||Campochiaro, Peter A: 53 articles (11/2015 - 02/2002)|
|7.||Zhang, Wei: 52 articles (12/2015 - 01/2002)|
|8.||Harris, Adrian L: 52 articles (04/2015 - 04/2002)|
|9.||Shibuya, Masabumi: 50 articles (10/2015 - 03/2002)|
|10.||Alitalo, Kari: 49 articles (06/2015 - 03/2002)|
03/01/2011 - "We found that the ratio of VEGF-A/sFLT-1 was increased not only in murine but also in human MA, and F-gene-deleted recombinant Sendai virus (rSeV/dF)-mediated secretion of human sFLT-1 by DCs augmented not only the activity of DCs themselves, but also dramatically improved the survival of tumor-bearing animals associated with enhanced CTL activity and its infiltration to peritoneal tumors. "
08/01/2014 - "An important question for the pediatric oncology research community, pharmaceutical companies, and regulatory agencies to address in planning for future clinical trials is whether existing data support a role for VEGF pathway targeted agents in contributing to a therapeutic pathway to cure for children with cancer."
12/01/2011 - "Pharmacological targeting of blood vessels, mainly through the VEGF signaling pathway, has proven effective in normalizing tumor vessels. "
01/01/2009 - "VEGF levels were highest in those who did not achieve complete remission after cancer therapy. "
11/01/2006 - "Since the tumor vascular network can impact the efficacy of anti-cancer therapies, these results suggest that VEGF expression may be important to consider in the treatment of cancer."
|2.||Colorectal Neoplasms (Colorectal Cancer)
08/15/2015 - "The clinical management of colorectal cancer patients has significantly improved because of the identification of novel therapeutic targets such as EGFR and VEGF. "
01/01/2011 - "Moreover, high P-LVD and high VEGF expression were significant negative prognostic parameters associated with a shorter disease-free interval in stage I colorectal cancer. "
11/01/2002 - "Early postoperative serum VEGF levels show significant fall and may help to identify the oncological status of colorectal cancer resections."
01/01/2015 - "Therefore, the simultaneous targeting of EGFR/VEGF and COX-2 may aid in blocking mCRC progression and improve the efficacy of existing therapies in colorectal cancer. "
02/01/2010 - "Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients."
10/17/2006 - "Levels of VEGF and of hypoxia-inducible factor 1alpha, elevated in the human MECs under hypoxia, were dramatically reduced or even suppressed in the presence of the ITPP-loaded RBCs. "
09/20/2012 - "In addition, to explore whether VEGF secreted by HIF-1α-AA-modified BMSCs plays an important role in preventing hypoxia-induced apoptosis and the possible mechanism involved, exogenous VEGF were applied and the similar protective effects on PC12 cells were observed in vitro. "
04/01/2011 - "On the one hand, neoangiogenesis driven by VEGF, if intact, ameliorates hypoxia, on the other, VEGF is a potent pro-inflammatory mediator and neoangiogenesis, if defective because interference by other pathologies exaggerates injury. "
07/01/2010 - "The mechanism seems to involve in inhibiting hypoxia-mediated activation of p-ERK1/2, it leads to a marked decrease in hypoxia-induced HIF-1alpha protein accumulation and VEGF secretion. "
06/01/2010 - "Combination treatment resulted in a marked inhibition of HIF-1 alpha expression levels in hypoxic cells and caused a significant reduction in the expression of activated phosphorylated AKT, ERK1/2, p-BAD and VEGF in both normoxia and hypoxia with greater levels of inhibition in hypoxia. "
|4.||Macular Degeneration (Age-Related Maculopathy)
01/01/2009 - "Since anti-VEGF treatment has been proven to achieve a significant improvement of visual acuity in a cohort of patients with neovascular age-related macular degeneration (AMD), macular surgery and particularly the macular translocation with 360 degrees retinotomy (FMT: full macular translocation) have lost their former popularity. "
09/01/2011 - "We retrospectively studied 40 eyes of 40 patients with neovascular age-related macular degeneration who were treated successfully with intravitreal anti-vascular endothelial growth factor injection. "
12/01/2008 - "Since the introduction of anti-VEGF drugs for the treatmet of CNV in age-related macular degeneration (AMD), visual acuity can be stabilised or improved in a significant number of patients. "
09/01/2003 - "These results strengthen the evidence for a critical role of the VEGF-KDR system in the development of CNV, indicating that KDR selective inhibitor might be beneficial for the treatment of intraocular angiogenic diseases, including age-related macular degeneration."
08/01/2014 - "Although anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration (AMD) results in improved vision overall, loss of substantial vision can occur. "
03/01/2006 - "Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia--a case report."
02/16/2001 - "Tissue ischemia and/or VEGF may stimulate capillary sprouting, but this response does not translate to a significant improvement in collateral flow. "
01/01/2015 - "In this work we report on therapeutic efficacy of CS from mouse ADSC transduced to express human vascular endothelial growth factor 165 a/a isoform (VEGF165), which showed potency to restore perfusion and protect tissue in a model of limb ischemia. "
01/01/2009 - "The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium."
01/01/2003 - "However, only combined VEGF(121)+TLMR therapy resulted in an improvement in regional myocardial blood flow in comparison with 1 week ischemia, indicating the efficient development of collateral circulation. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|5.||Epidermal Growth Factor Receptor (EGF Receptor)
|6.||Messenger RNA (mRNA)
|8.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|9.||Small Interfering RNA (siRNA)
|10.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)